C-reactive Protein Testing Market To Reach $5.67 Billion By 2030

C-Reactive Protein Testing Market Growth & Trends

The global C-reactive protein testing market size is expected to reach USD 5.67 billion by 2030 and is projected to grow at a CAGR of 0.26% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of C-reactive protein (CRP) testing can be attributed to significant research activities aimed at exploring various applications of testing. These research efforts are further facilitated by the presence of both private and public agencies that provide funding to expedite research in this field. The market is anticipated to witness significant growth owing to advancements in nanotechnological tools. These advancements offer promising opportunities to develop portable bioanalytical assays that possess attributes, such as high specificity, sensitivity, rapid response time, and the ability to perform multiplexing for accurate disease diagnosis and monitoring at the point of care.

These advancements are expected to drive the demand for CRP testing during the forecast period. Furthermore, an increase in strategic deals and developments, as well as higher investments in research and development has fueled the growth. The COVID-19 pandemic has had a considerable impact on the market, as CRP is considered a crucial biomarker for assessing the severity of infection and inflammation. As a result, there is an increased demand for services and products. Leading companies, such as Abbott, provide supportive tools for CRP testing specifically for SARS-CoV-2 infection, further contributing to market growth. Moreover, key players increased focus on product launches and developments in point-of-care CRP tests, which is projected to further fuel the market's growth in the coming years.

For instance, in July 2022, Bloom Diagnostics introduced the Bloom Inflammation Test, a semi-automated testing kit designed for the quantification of CRP levels in the blood. This single-use kit aids in the detection of inflammation within the body. The growth of the marketplace is expected to be further stimulated by the establishment of testing facilities. In June 2021, Trivitron Healthcare unveiled a mobile laboratory for COVID-19 diagnostics, enabling testing services in various regions of India, including rural, urban, and remote areas. This indigenous laboratory offers a range of tests, including CLIA/Elisa tests for inflammatory markers, such as a CRP, IL-6, and D-Dimer, as well as rapid antigen tests, RT-PCR tests, CLIA/Elisa Antibodies Tests IgM and IgG, and others.

North America held the largest revenue share of 39.42% in 2022 and is expected to maintain its share during the forecast period due to the increasing prevalence of cardiovascular diseases, a steady stream of product launches, presence of established market players, technological advancements, and well-developed healthcare infrastructure. Asia Pacific is projected to grow at the fastest CAGR of 0.49% from 2023 to 2030. The COVID-19 pandemic originated in China. Being the potential biomarker for determining the severity of the infection, the demand for CRP testing is expected to increase shortly. Key players operating in the global industry are constantly focusing on product launches and geographical expansion to maintain their presence.

 Request a free sample copy or view report summary: C-reactive Protein Testing Market Report

C-reactive Protein Testing Market Report Highlights

• Based on assay type, the immunoturbidimetric assay segment held the largest revenue share of 48.53% in 2022. Owing to the introduction of a highly sensitive, automated, and cost-effective immunoturbidimetric assay that offers a wide measuring range for accurately detecting the levels of CRP in samples

• Based on detection ranges, the hs-CRP segment dominated the market in 2022 with a revenue share of approximately 42.80%. The hs-CRP features a broad detection range than that compared to the conventional CRP

• Based on disease area type, the cardiovascular diseases segment dominated the market with the largest market share in 2022 and is anticipated to dominate the market throughout the forecast period. The increase in the prevalence of CVDs is the major factor contributing to the growth of the CRP testing market

• The hospitals end-user segment dominated with a market share of 28.01% in 2022 due to the increased adoption of CRP testing in hospitals, particularly in response to the COVID-19 pandemic. This has led to a higher testing rate and contributed to the segment's growth

• Furthermore, the marketplace is experiencing growth due to the increasing prevalence of chronic heart diseases and cancers. These conditions contribute significantly to the market's expansion as there is a rising demand for CRP testing in the diagnosis, management, and monitoring of these diseases

C-reactive Protein Testing Market Segmentation

Grand View Research has segmented the global C-reactive protein testing market based on assay type, detection range, disease area, end-use, and region:

CRP Testing Assay Type Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoturbidimetric Assay

• ELISA

  • Clinical

  • Non-clinical

• Chemiluminescence Immunoassay

• Others

CRP Testing Detection Range Outlook (Revenue, USD Million, 2018 - 2030)

• hs-CRP

• Conventional CRP

• cCRP

CRP Testing Disease Area Outlook (Revenue, USD Million, 2018 - 2030)

• Cardiovascular Diseases

• Cancer

• Rheumatoid Arthritis

• Inflammatory Bowel Disease

• Endometriosis

• Lupus

• Others

CRP Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Clinics

  • By Entity

    • Physician Offices

    • Small Clinics

    • Others

  • By Settings

    • Urban Setting

    • Rural Setting

• Hospitals

  • Urban Setting

  • Rural Setting

• Laboratories

  • Urban Setting

  • Rural Setting

• Assisted Living Healthcare Facilities

  • Urban Setting

  • Rural Setting

• Home

• Others

CRP Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • India

  • Japan

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the C-reactive Protein Testing Market

• Thermo Fisher Scientific, inc.

• F. Hoffmann-La Roche Ltd.

• Danaher

• Quest Diagnostics

• Siemens Healthineers AG

• Abbott

• Merck KGaAA

• Zoetis

• Ortho Clinical Diagnostics

• Getein Biotech, Inc.

• HORIBA, Ltd

• Randox Laboratories Ltd.

• BODITECH MED, INC.

• Aidian